Cantor Fitzgerald Starts CytomX Therapeutics (CTMX) at Overweight
Tweet
Share
E-mailGet Alerts CTMX Hot Sheet
Price: $3.59 +6.85%
Rating Summary:
14 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 6 | New: 33
Rating Summary:
14 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 6 | New: 33
Join SI Premium – FREE
Cantor Fitzgerald initiates coverage on CytomX Therapeutics (NASDAQ: CTMX) with a Overweight rating and a price target of $35.00.
Analyst Mara Goldstein sees potential for the company to create a best-in-class pipeline among bio-therapeutic companies.
For an analyst ratings summary and ratings history on CytomX Therapeutics click here. For more ratings news on CytomX Therapeutics click here.
Shares of CytomX Therapeutics closed at $20.04 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Chardan Assumes Rocket Pharmaceuticals (RCKT) at Buy
- Oddity Tech Ltd (ODD) PT Raised to $16 at Truist Securities
- Protagonist Therapeutics (PTGX) PT Raised to $190 at BMO Capital
Create E-mail Alert Related Categories
Analyst Comments, New CoverageRelated Entities
Cantor Fitzgerald, Mara GoldsteinSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
